Stock 0AAJ POLYPEPTIDE GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials PolyPeptide Group AG London S.E.

Equities

0AAJ

CH1110760852

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 12:59:00 07/05/2024 BST 		5-day change 1st Jan Change
31.25 CHF +90.20% Intraday chart for PolyPeptide Group AG -6.02% +78.37%
03-12 PolyPeptide Group AG Provides Earnings Guidance for 2024 CI
03-12 Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 4,371 842.2 620.9 1,062 - -
Enterprise Value (EV) 1 4,264 836.4 620.9 1,135 1,178 1,210
P/E ratio 90 x 107 x -12.1 x -123 x 62.7 x 27.9 x
Yield 0.22% - - - 0.14% 0.6%
Capitalization / Revenue 15.5 x 3 x 1.91 x 3.04 x 2.58 x 2.18 x
EV / Revenue 15.1 x 2.98 x 1.91 x 3.25 x 2.86 x 2.48 x
EV / EBITDA 50.3 x 21.6 x -103 x 41.4 x 18.2 x 11.8 x
EV / FCF -257 x -11.4 x - -24.6 x -89.9 x -100 x
FCF Yield -0.39% -8.76% - -4.07% -1.11% -1%
Price to Book 10.1 x 2 x - 2.71 x 2.58 x 2.37 x
Nbr of stocks (in thousands) 33,031 32,938 32,944 32,970 - -
Reference price 2 132.3 25.57 18.85 32.21 32.21 32.21
Announcement Date 15/03/22 14/03/23 12/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 223 282.1 281 324.9 349.5 411.2 487
EBITDA 1 - 84.8 38.67 -6 27.4 64.87 102.4
EBIT 1 - 64.2 12.61 -36.47 -4.091 30.16 61.6
Operating Margin - 22.76% 4.49% -11.23% -1.17% 7.33% 12.65%
Earnings before Tax (EBT) 1 - 59.85 7.567 -58.24 -12.55 17.7 41.6
Net income 1 31.34 47.26 7.767 -51.44 -12.22 14.9 38.43
Net margin 14.05% 16.75% 2.76% -15.83% -3.5% 3.62% 7.89%
EPS 2 - 1.470 0.2400 -1.560 -0.2624 0.5134 1.152
Free Cash Flow 1 - -16.61 -73.3 - -46.2 -13.1 -12.1
FCF margin - -5.89% -26.09% - -13.22% -3.19% -2.48%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - 0.2909 - - - 0.0444 0.1918
Announcement Date 15/03/21 15/03/22 14/03/23 12/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 135.1 133.7 147.3 131.8 191.5 131.8 212.6
EBITDA 1 39.89 26.71 - -19.39 13.4 0.7 26.8
EBIT 1 - 15.48 - - -2.004 -14.9 10.7
Operating Margin - 11.58% - - -1.05% -11.31% 5.03%
Earnings before Tax (EBT) - - - - - - -
Net income 1 - 10.25 -2.48 -34.27 - -19.8 8.7
Net margin - 7.67% -1.68% -25.99% - -15.02% 4.09%
EPS - 0.3100 - -1.040 - - -
Dividend per Share - - - - - - -
Announcement Date 17/08/21 18/08/22 14/03/23 15/08/23 12/03/24 - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 73.6 116 148
Net Cash position 1 - 107 5.8 - - - -
Leverage (Debt/EBITDA) - - - - 2.687 x 1.79 x 1.444 x
Free Cash Flow 1 - -16.6 -73.3 - -46.2 -13.1 -12.1
ROE (net income / shareholders' equity) - 16.7% 1.84% - -2.49% 4.35% 9.85%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 13.10 12.80 - 11.90 12.50 13.60
Cash Flow per Share 2 - 1.780 0.1700 - 0.5800 1.500 2.740
Capex 1 - 74 78.8 - 60.4 69.9 80.8
Capex / Sales - 26.22% 28.03% - 17.3% 16.99% 16.6%
Announcement Date 15/03/21 15/03/22 14/03/23 12/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PolyPeptide Group AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
32.21 EUR
Average target price
25.12 EUR
Spread / Average Target
-21.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PPGN Stock
  4. 0AAJ Stock
  5. Financials PolyPeptide Group AG